Monoclonal Antibody to Androgen Receptor (AR)
Code | Size | Price |
---|
MAB252Ra22-20ul | 20ul | £94.00 |
Quantity:
MAB252Ra22-100ul | 100ul | £180.00 |
Quantity:
MAB252Ra22-200ul | 200ul | £244.00 |
Quantity:
MAB252Ra22-1ml | 1ml | £563.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
AIS; DHTR; HUMARA; KD; NR3C4; SBMA; SMAX1; TFM; Dihydrotestosterone receptor; Nuclear Receptor Subfamily 3,Group C,Member 4; Testicular Feminization; Kennedy Disease
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG2b Kappa
Immunogen:
RPB252Ra01-Recombinant Androgen Receptor (AR)
Item Name:
Androgen Receptor
Potency (Clone Number):
D4
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Androgen Receptor (AR) | RPB252Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||